Market Closed - Nasdaq 04:00:00 2024-04-15 pm EDT 5-day change 1st Jan Change
17.69 USD -1.28% Intraday chart for InMode Ltd. -10.61% -20.46%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Barclays Adjusts Price Target on InMode to $33 From $34, Maintains Overweight Rating MT
Sector Update: Health Care Stocks Edge Higher Pre-Bell Tuesday MT
InMode Lowers Fiscal 2024 Revenue Forecast, Issues Fiscal Q1 Guidance MT
Inmode Ltd. Provides Revenue Guidance for the First Quarter of 2024 CI
Glass Lewis Issues Shareholders Alert on InMode Ahead of Annual Meeting MT
InMode Seeks M&A CI
Transcript : InMode Ltd. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 03:05 PM
Barclays Adjusts Price Target on InMode to $34 From $32, Maintains Overweight Rating MT
UBS Adjusts InMode Price Target to $26 From $24, Maintains Neutral Rating MT
InMode's Q4 Non-GAAP Earnings, Revenue Fall; 2024 Guidance Issued MT
Transcript : InMode Ltd., Q4 2023 Earnings Call, Feb 13, 2024
Earnings Flash (INMD) INMODE Posts Q4 EPS $0.71, vs. Street Est of $0.67 MT
InMode Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
InMode Ltd. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
North American Morning Briefing : Stocks Seen -2- DJ
Barclays Trims Price Target on InMode to $32 From $33, Maintains Overweight Rating MT
InMode Ltd. Provides Revenue Guidance for the Fourth Quarter, Full Year of 2023 and for the Full Year of 2024 CI
InMode Ltd. Revises Earnings Guidance for the Full Year 2023 CI
UBS Downgrades InMode to Neutral From Buy, Cuts Price Target to $24 From $52 MT
Transcript : InMode Ltd., Q3 2023 Earnings Call, Nov 02, 2023
Earnings Flash (INMD) INMODE Reports Q3 EPS $0.61, vs. Street Est of $0.63 MT
InMode Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
InMode Files Patent Infringement Complaint Against BTL Industries MT
InMode Issues Q3 Non-GAAP Earnings, Revenue Expectations; 2023 Revenue Guidance Cut MT
InMode Ltd. Revises Revenue Guidance for the Full Year 2023 CI
Chart InMode Ltd.
More charts
Inmode Ltd is an Israel-based global provider of energy-based, minimally-invasive surgical medical treatment solutions. Company's products and solutions are primarily designed to address three energy-based treatment categories comprised of: face and body contouring; medical aesthetics; and women's health. The Company have developed and commercialized products utilizing medically-accepted RF energy technology, which can penetrate deep into the subdermal fat, allowing adipose tissue remodeling. It's RF energy-based proprietary technologies - Radio Frequency Assisted Lipolysis (RFAL), Deep Subdermal Fractional RF, Simultaneous Fat Destruction and Skin Tightening and Deep Heating Collagen Remodeling for skin and human natural openings- represent a paradigm shift in the minimally-invasive aesthetic solutions market. These technologies are used by physicians to remodel subdermal adipose, or fatty tissue in a variety of procedures.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
17.69 USD
Average target price
27.6 USD
Spread / Average Target
+56.02%
Consensus
  1. Stock Market
  2. Equities
  3. INMD Stock
  4. News InMode Ltd.
  5. Needham Adjusts InMode's Price Target to $58 From $82 on 'Peer Multiple Compression,' Reiterates Buy Rating